Results

1–10 of 34 results for AMD clinical trials

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States
Rebecca Soares, MD
Annual Meeting Talks
2021
Effect of Adjuvant Topical Dorzolamide-Timolol Versus Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Jason Hsu, MD
On Demand Cases, Courses, and Papers
2020
Assessment of Progression of Geographic Atrophy in the FILLY Study
David R Lally, MD
On Demand Cases, Courses, and Papers
2020
Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
Annual Meeting Talks
2019
Episode 28: Brolucizumab for wet AMD (HAWK and HARRIER) - Dr. Pravin Dugel
Keyvan Koushan, MD, FRCSC
Member Podcasts
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients With nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Annual Meeting Talks
2019
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
2019